CN Patent

CN108135923B — 靶向超氧化物歧化酶1（sod1）的核酸分子

Assigned to Phio Pharmaceuticals Corp · Expires 2021-03-02 · 5y expired

What this patent protects

本发明的一些方面涉及用于治疗ALS的方法，其包括向有此需要的对象施用治疗有效量的针对编码超氧化物歧化酶1(SOD1)之基因的核酸分子。

USPTO Abstract

本发明的一些方面涉及用于治疗ALS的方法，其包括向有此需要的对象施用治疗有效量的针对编码超氧化物歧化酶1(SOD1)之基因的核酸分子。

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: CN108135923B
Jurisdiction: CN
Classification: —
Expires: 2021-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Phio Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.